arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

REGENXBIO Inc.

RGNX
$10.72 ▼ -0.54 (-4.84%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
14 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

REGENXBIO Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $552.9M
Dividend Yield
Revenue Growth 104.5%
Op. Margin -94.6%
ROIC -156.9%
FCF / Share $-2.45
Trailing P/E
Price / Book 5.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$170.44M
↑ +104.5%
Net Income Profit after all expenses
$-193.88M
↑ +14.6%
Operating Margin Operating profit as % of sales
-94.6%
↑ +66.2% 2th
FCF / Share Free cash flow per share
$-2.45
↑ +30.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
3
Cash Quality
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 14 years · 50 quarters